The FDA approved depemokimab (Exdensur) as the first ultra-long-acting biologic with twice-yearly dosing approved for patients with severe asthma with an eosinophilic phenotype, GSK announced. The ...

A new option for hard-to-control asthma: The FDA has approved Exdensur (depemokimab-ulaa) as an add-on maintenance treatment for people with severe asthma. Designed to reduce flare-ups: The injectable ...

Depemokimab-ulaa (Exdensur) is approved for severe asthma with an eosinophilic phenotype, offering protection with just two doses annually. Phase 3 trials demonstrated significant reductions in asthma ...

What Is Exdensur, and Why Does It Matter? Exdensur (depemokimab) is a new type of ultra long-acting biologic medicine approved by the FDA as an add-on maintenance treatment for severe eosinophilic ...

LONDON, Dec 16 (Reuters) - The U.S. health regulator has approved GSK's (GSK.L), opens new tab add-on treatment for severe asthma, offering a less frequently dosed option, but rejected its use for ...

GSK’s depemokimab, a long-acting biologic that’s key in the British pharma’s growth plan, has won European regulatory approval for two inflammatory disease indications. The European Medicines Agency's ...

Please provide your email address to receive an email when new articles are posted on . The COVID-adjusted annualized asthma exacerbation rate dropped by 46%. Mean cumulative oral corticosteroid dose ...

Asthma care continues to develop, particularly in how treatment and long-term management are approached. This article outlines current treatment and management recommendations for patients aged 12 and ...

Scientists found that RSV infection early in life can set the stage for childhood asthma, particularly in kids already genetically prone to allergies. The virus appears to skew the developing immune ...

People with severe asthma sometimes rely on daily steroid pills, which raise the risk of diabetes, infections and bone problems. Now, a study supports the idea that a monthly antibody injection is a ...

Please provide your email address to receive an email when new articles are posted on . You've successfully added to your alerts. You will receive an email when new content is published. Click Here to ...